Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
USERS' SCORE
Good
Based on 5 Reviews
8.3
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Calcium (from Calcium-Magnesium Inositol Hexaphosphate)
100 mg
8%
Inositol Hexaphosphate (from Calcium-Magnesium Inositol Hexaphosphate)
500 mg
†
Top Medical Research Studies
9
IP6 potentially prevents prostate cancer
We evaluated how inositol hexaphosphate (IP6), a natural compound found in various foods, influences the growth and development of prostate cancer in a special group of mice known as TRAMP. The study involved feeding these male mice either regular water or water containing 2% IP6 at different stages of their growth – starting at 4, 12, 20, and 30 weeks of age – for a period of about 8 to 15 weeks.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Read More
9
In our exploration of the role of inositol in prostate cancer, we found that a specific form of inositol derived from the IMPA1 enzyme plays a crucial role in the development and maintenance of prostate cancer stem cells (PCSCs). These PCSCs are important because they contribute to the progression of castration-resistant prostate cancer (CRPC), particularly after patients undergo androgen ablation therapy (ABT).
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
Read More
8
We examined how Myo-inositol, a natural compound, influences prostate cancer cells, specifically the DU-145 cell line. The study aimed to evaluate its potential as a treatment by determining how it affects cell survival and protein expression.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
Read More
Most Useful Reviews
9
Cancer management support
7 people found this helpful
I have been taking IP6 for four years after my cancer operation. My initial outlook was grim, but following a friend's recommendation, I continued taking them. I’m still cancer-free, so I’ll keep using them as a precaution.
Read More
7.5
Cancer cell reduction
3 people found this helpful
Jarrow produces quality supplements. I take one or two daily to decrease my chances of developing prostate cancer. Many studies support IP6 in killing cancer cells and its effectiveness as a chelator.
Read More
7.5
Supports immune health
17 people found this helpful
I take this drug for herpes to strengthen my immune system. IP6 also supports antioxidant and cellular health, promoting prostate cancer, breast, colon, and liver health. It aids insulin and calcium metabolism, encourages hair growth, and helps transport fat in the liver.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
- All Researches
9
In our exploration of the role of inositol in prostate cancer, we found that a specific form of inositol derived from the IMPA1 enzyme plays a crucial role in the development and maintenance of prostate cancer stem cells (PCSCs). These PCSCs are important because they contribute to the progression of castration-resistant prostate cancer (CRPC), particularly after patients undergo androgen ablation therapy (ABT).
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
Read More
9
IP6 potentially prevents prostate cancer
We evaluated how inositol hexaphosphate (IP6), a natural compound found in various foods, influences the growth and development of prostate cancer in a special group of mice known as TRAMP. The study involved feeding these male mice either regular water or water containing 2% IP6 at different stages of their growth – starting at 4, 12, 20, and 30 weeks of age – for a period of about 8 to 15 weeks.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Read More
8
We examined how Myo-inositol, a natural compound, influences prostate cancer cells, specifically the DU-145 cell line. The study aimed to evaluate its potential as a treatment by determining how it affects cell survival and protein expression.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
Read More
8
We examined the potential of a compound called myo-inositol-hexakisphosphate (Zn-InsP6) to lessen the side effects of a treatment known as radium-223 dichloride for prostate cancer patients. This treatment is commonly used for those suffering from bone metastases, but there's a concern that some of the emitted radiation can be absorbed into the bloodstream from the intestines, leading to unwanted exposure.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cancer management support
7 people found this helpful
I have been taking IP6 for four years after my cancer operation. My initial outlook was grim, but following a friend's recommendation, I continued taking them. I’m still cancer-free, so I’ll keep using them as a precaution.
Read More
7.5
Cancer cell reduction
3 people found this helpful
Jarrow produces quality supplements. I take one or two daily to decrease my chances of developing prostate cancer. Many studies support IP6 in killing cancer cells and its effectiveness as a chelator.
Read More
7.5
Supports immune health
17 people found this helpful
I take this drug for herpes to strengthen my immune system. IP6 also supports antioxidant and cellular health, promoting prostate cancer, breast, colon, and liver health. It aids insulin and calcium metabolism, encourages hair growth, and helps transport fat in the liver.
Read More
7.5
Slowed progression
9 people found this helpful
My husband takes this to slow the progression of prostate cancer. So far, it seems to be helping.
Read More
7.5
Effective anti-cancer supplement
5 people found this helpful
IP6 is a great anti-cancer supplement!
Read More
Frequently Asked Questions
9
Cancer management support
7 people found this helpful
I have been taking IP6 for four years after my cancer operation. My initial outlook was grim, but following a friend's recommendation, I continued taking them. I’m still cancer-free, so I’ll keep using them as a precaution.
7.5
Cancer cell reduction
3 people found this helpful
Jarrow produces quality supplements. I take one or two daily to decrease my chances of developing prostate cancer. Many studies support IP6 in killing cancer cells and its effectiveness as a chelator.
7.5
Supports immune health
17 people found this helpful
I take this drug for herpes to strengthen my immune system. IP6 also supports antioxidant and cellular health, promoting prostate cancer, breast, colon, and liver health. It aids insulin and calcium metabolism, encourages hair growth, and helps transport fat in the liver.
8
We examined how Myo-inositol, a natural compound, influences prostate cancer cells, specifically the DU-145 cell line. The study aimed to evaluate its potential as a treatment by determining how it affects cell survival and protein expression.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
To do this, we treated the DU-145 cells with varying doses of Myo-inositol and assessed cell viability using a method called the trypan blue exclusion assay. Our findings showcased that Myo-inositol significantly decreased cell viability, with an IC50 value of 0.06 mg/ml, indicating that it could hinder cancer cell growth effectively.
Moreover, we explored the changes in protein expression brought about by Myo-inositol treatment. Our proteomic analysis revealed notable differences in the proteins expressed in treated cells compared to untreated ones. There were key alterations in proteins associated with preventing cell death and managing stress, suggesting that Myo-inositol might engage in important cancer-fighting pathways.
Overall, our results suggest that Myo-inositol exhibits considerable anticancer effects on prostate cancer cells. Although it shows promise as a supplementary treatment, we stress the need for further research to unveil the precise mechanisms of action and explore its potential in combination therapies for advanced prostate cancer.
9
In our exploration of the role of inositol in prostate cancer, we found that a specific form of inositol derived from the IMPA1 enzyme plays a crucial role in the development and maintenance of prostate cancer stem cells (PCSCs). These PCSCs are important because they contribute to the progression of castration-resistant prostate cancer (CRPC), particularly after patients undergo androgen ablation therapy (ABT).
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
We observed that when the IMPA1 gene was conditionally knocked out in the prostate of a mouse model, the number and characteristics of these cancer stem cells were significantly reduced. This finding suggests that inositol not only supports the survival of these cells but also contributes to the aggressive nature of CRPC.
Furthermore, inositol interacts with another protein named IMPDH2 to create guanylate nucleotides, necessary for the survival of PCSCs, demonstrating a complex metabolic relationship that deepens our understanding of this cancer's resistance to treatment. The study also highlighted that the INMPA1/inositol/IMPDH2 pathway is often upregulated in human prostate cancer and that this overexpression correlates with poorer survival rates.
Targeting this pathway could be a promising strategy. Our findings show that disrupting the IMPA1/inositol/IMPDH2 axis can reverse CRPC and help overcome resistance to ABT in various experimental models.
9
IP6 potentially prevents prostate cancer
We evaluated how inositol hexaphosphate (IP6), a natural compound found in various foods, influences the growth and development of prostate cancer in a special group of mice known as TRAMP. The study involved feeding these male mice either regular water or water containing 2% IP6 at different stages of their growth – starting at 4, 12, 20, and 30 weeks of age – for a period of about 8 to 15 weeks.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
Pathological evaluations at the end of the study revealed some encouraging results. The IP6 treatment seemed to halt tumor progression earlier on, and it significantly reduced the incidence of more severe forms of the disease by around 55% to 70%. This finding suggests that IP6 could have a crucial role in preventing prostate cancer from advancing in severity.
Furthermore, we explored the effects of IP6 on cancer stem cells (CSCs), a small group of cells within tumors that can drive cancer growth. The results indicated that IP6 might help in reducing these CSCs in prostate tumors. In laboratory tests, we also found that IP6 treatment dramatically decreased the number of floating prostate cancer stem cell clusters by approximately 90%.
Overall, these findings suggest that IP6 holds significant promise as a preventive measure against prostate cancer, particularly at earlier stages of the disease.
8
We examined the potential of a compound called myo-inositol-hexakisphosphate (Zn-InsP6) to lessen the side effects of a treatment known as radium-223 dichloride for prostate cancer patients. This treatment is commonly used for those suffering from bone metastases, but there's a concern that some of the emitted radiation can be absorbed into the bloodstream from the intestines, leading to unwanted exposure.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
In our investigation, we found that Zn-InsP6 can effectively bind to radium. This binding may reduce the absorption of radium into the body after it is expelled into the intestines through waste. Through experiments conducted on mice, we discovered that those treated with Zn-InsP6 had significantly lower levels of radioactivity in their bones compared to the control group, suggesting that the compound does indeed limit radium absorption.
However, it is important to note that our study did not directly assess the impact of inositol on prostate cancer outcomes. While there's potential for Zn-InsP6 to minimize radiation exposure and its side effects, we did not evaluate any improvements in cancer treatment outcomes directly attributable to inositol. Thus, while it's a promising area of research, we need further studies to draw solid conclusions about its effectiveness in prostate cancer management.
References
- Islam MJ, Muntaha S, Masum MM, Nowshin S, Salam S, et al. Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line. Asian Pac J Cancer Prev. 2024;25:4447. doi:10.31557/APJCP.2024.25.12.4447
- Hsu CC, Wang G, Li CF, Zhang X, Cai Z, et al. IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation. J Exp Med. 2024;221. doi:10.1084/jem.20231832
- Raina K, Kandhari K, Jain AK, Ravichandran K, Maroni P, et al. Stage-Specific Effect of Inositol Hexaphosphate on Cancer Stem Cell Pool during Growth and Progression of Prostate Tumorigenesis in TRAMP Model. Cancers (Basel). 2022;14. doi:10.3390/cancers14174204
- Ogawa K, Higashi T, Mishiro K, Wakabayashi H, Shiba K, et al. Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases. Sci Rep. 2020;10:11917. doi:10.1038/s41598-020-68846-x
